Article

Umbilical Cord Blood May Contain the Next Eczema Treatment

Although preclinical trials have shown that mesenchymal stem cells (MSCs) are therapeutically effective against atopic dermatitis, actual clinical studies had not yet confirmed it – until now.

dermatology, atopic dermatitis, eczema

Although preclinical trials have shown that mesenchymal stem cells (MSCs) are therapeutically effective against atopic dermatitis, actual clinical studies had not yet confirmed it — until now.

MSCs are typically found in bone marrow, but it can be isolated from other locations such as the fallopian tube, fetal liver, fetal lung, and even from umbilical cord blood.

“This study is a first-in-class study demonstrating that adults with moderate-to-severe atopic dermatitis responded to a treatment of stem cells derived from umbilical cord blood,” senior author Tae-Yoon Kim, MD, PhD, from The Catholic University of Korea in South Korea, explained in a news release.

This discovery was made in two clinical trials consisting of 34 patients with moderate-to-severe eczema, as described in Stem Cells. The participants were split to either receive a low dose or high dose of the human umbilical cord blood-derived MSCs subcutaneously.

  • Related: Dermatologists Say Kids with Eczema Can Shower Every Day

Scores were measured based on the Eczema Area and Severity Index (EASI), Investigator’s Global Assessment (IGA), and Severity Scoring for Atopic Dermatitis (SCORAD). Outcomes were reported after one month for the first study and three months for the second.

“The single treatment of stem cells in patients resulted in the significant and persistent improvement in disease symptoms throughout the follow-up period of 12 weeks,” Kim continued.

For those who received high dose, 55% showed a 50% reduction in EASI score. In addition, these patients had a reduction in IGA (33%) and SCORAD (50%) scores.

The researchers said that immune-related markers of atopic dermatitis also significantly decreased. Pruritus (severe itching) scores reduced by 58% with the high dose.

None of the patients discontinued the study due to side effects and no serious adverse events occurred from the treatment.

Also on MD Magazine >>> Crisaborole Ointment May Be Better Tolerated than Other Topical Treatments in Patients with Atopic Dermatitis

Related Videos
Discussing 140-Week Data on Upadacitinib for Atopic Dermatitis, with Raj Chovatiya, MD, PhD
ADORING Trial Open-Label Extension: Tapinarof Cream 1% Results in Atopic Dermatitis
Linda Stein Gold, MD: Discussing New Phase 3b Data on Lebrikizumab for Atopic Dermatitis
Andrea Murina, MD: Drug Pipeline for Hidradenitis Suppurativa
Omega-3 Supplements for Rosacea and Other Tips for Dermatologists, with Andrea Murina, MD
Methods to Manage Psoriasis Using Oral Therapies, with Andrea Murina, MD
2 Additional Clinical Pearls for Dermatologists, with Eingun James Song, MD
2 Helpful Clinical Tips for Dermatologists, with Eingun James Song, MD
What Are Some Other Methods To Manage Skin Cancer Outside of Biopsies?
© 2024 MJH Life Sciences

All rights reserved.